Cardiology pp 535-546 | Cite as

Limitation of Infarct Size by Pharmacological Interventions

  • A. Waldenström
  • J. Herlitz
  • F. Waggstein
  • Å. Hjalmarson
By the introduction of coronary care units the mortality in acute myocardial infarction decreased from about 40% to about 15–20%. This was mainly due to:
  1. (1)

    good monitoring of patients with early detection of arrhythmias,

  2. (2)

    effective antiarrhythmic drugs (e.g. lidocaine),

  3. (3)

    well trained staff with early and skilled handling of cardiac standstills.



Acute Myocardial Infarction Infarct Size Coronary Care Unit Myocardial Infarct Size Suspected Acute Myocardial Infarction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    O. Kibe and N. J. Nilsson, Observations on the diagnostic and prognostic value of some enzyme tests in myocardial infarction, Acta.Med.Scand. 182:597–610 (1967).PubMedCrossRefGoogle Scholar
  2. 2.
    W. F. Kluge, Prognostic value of serum creatine Phosphokinase levels in myocardial infarction, Northwest Med, Sept 1979, pp.847–853.Google Scholar
  3. 3.
    B. L. Chapman, Correlation of mortality rate and serum enzymes in myocardial infarction. Test of efficiency of coronary care, Br.Heart J. 33:643–646 (1971).PubMedCrossRefGoogle Scholar
  4. 4.
    S. Hofvendahl, Influence of treatment in a coronary care unit on prognosis in acute myocardial infarction. A controlled study in 271 cases, Acta Med. Scand.. Suppl 519:9–78 (1971).Google Scholar
  5. 5.
    B. E. Sobel, G. F. Bresnahan, W. E. Shell and R. D. Yoder, Estimation of infarct size in man and its relation to prognosis, Circulation 46:640–648 (1972).PubMedCrossRefGoogle Scholar
  6. 6.
    M. M. Scheinman and J. A. Abbott, Clinical significance of transmural versus nontransmural electrocardiographic changes in patients with acute myocardial infarction, Am.J.Med.. 55: 602–607 (1973).PubMedCrossRefGoogle Scholar
  7. 7.
    C. Helmers, Short- and long-term prognostic indices in acute myocardial infarction. A study of 606 patients initially treated in a coronary care unit, Acta Med.Scand. Suppl 555: 1–86 (1973).Google Scholar
  8. 8.
    R. Henning, T. Lundman and R. Maasing, Prognostic evaluation by means of automatic interaction detector analysis, Acta Med. Scand. Suppl 578:11–31 (1975).Google Scholar
  9. 9.
    A. Vedin, L. Wilhelmsen, H. Wedel, B. Pettersson, C. Wilhelmsson, D. Elmfeldt and G. Tibblin, Prediction of cardiovascular deaths and non-fatal reinfarctions after myocardial infarction, Acta Med.Scand. 201:309–316 (1977).PubMedCrossRefGoogle Scholar
  10. 10.
    R. Nordlander and O. Nyquist, Mortality, arrhythmias and pump failure in acute myocardial infarction in relation to estimated infarct size, Acta Med.Scand. 206:65–71 (1979).PubMedCrossRefGoogle Scholar
  11. 11.
    P. L. Thompson, E. E. Fletcher and V. Katavatis, Enzymatic indices of myocardial necrosis: influence on short- and long-term prognosis after myocardial infarction, Circulation 59:113–119 (1979).PubMedCrossRefGoogle Scholar
  12. 12.
    S. Thanavaro, R. J. Krone, R. E. Kleiger, M. A. Province, J. P. Miller, V. R. DeMello and G. C. Oliver, In-hospital prognosis of patients with first nontransmural and transmural infarctions, Circulation 61:29–33 (1980).PubMedCrossRefGoogle Scholar
  13. 13.
    W. E. Shell and B. E. Sobel, Deleterious effects of increased heart rate on infarct size in the conscious dog, Am.J.Cardiol. 31:474–478 (1973).PubMedCrossRefGoogle Scholar
  14. 14.
    P. R. Maroko, P. Libby, T. W. Dovell, B. E. Sobel, J. Ross Jr and E. Braunwald, Precordial S-T segment elevation mapping: An atraumatic method for assessing alterations in the extent of myocardial ischemic injury, Am.J.Cardiol. 29:223–230 (1972).PubMedCrossRefGoogle Scholar
  15. 15.
    J. Herlitz, Bedömning och begränsning av hjärtinfarktens storlek. En interventionsstudie med metoprolol, Thesis, Göteborg (1982).Google Scholar
  16. 16.
    J. Herlitz, Å. Hjalmarson, K. Swedberg, F. Waagstein and A. Waldenstöm, A double-blind trial of metoprolol in acute myocardial infarction. Effect on infarct size, clinical findings and 1-year mortality, Abstr. (American Heart Association, 55th Sessions.) Circulation (in press).Google Scholar
  17. 17.
    Å. Hjalmarson, D. Elmfeldt, J. Herlitz, S. Holmberg, I. Málek, G. Nyberg, L. Rýden, K. Swedberg, A. Vedin, F. Waagstein, A. Waldenström, J. Waldenstrom, H. Wedel, L. Wilhelmsen and C. Wilhelmsson, Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial, Lancet ii:823–828 (1981).CrossRefGoogle Scholar
  18. 18.
    P. R. Maroko, L. D. Hillis, J. E. Muller, L. Tavazzi, G. R. Heyndrickx, M. Ray, M. Chiariello, A. Distante, J. Askenazi, J. Salerno, J. Carpentier, N. I. Reshetnaya, P. Radvany, P. Libby, D. S. Raabe, E. I. Chazov, P. Bobba and E. Braunwald, Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction, New Engl.J.Med. 296:898–903 (1977).PubMedCrossRefGoogle Scholar
  19. 19.
    S. Saltissi, P. S. Robinson, D. J. Coltart, M. M. Webb-Peploe and D. N. Croft, Effects of early administration of a highly purified hyaluronidase preparation (GL enzyme) on myocardial infarct size, Lancet i:867–870 (1982).CrossRefGoogle Scholar
  20. 20.
    E. J. Flint, J. de Giovanni, P. J. Cadigan, P. Lamb and B. L. Pentecost, Effect of GL enzyme (a highly purified form of hyaluronidase) on mortality after myocardial infarction, Lancet i : 871–874 (1982).CrossRefGoogle Scholar
  21. 21.
    A. Henderson, R. W. F. Campbell and D. G. Julian, Effect of a highly purified hyaluronidase preparation (GL enzyme) on electrocardiographic changes in acute myocardial infarction, Lancet i:874–876 (1982).CrossRefGoogle Scholar
  22. 22.
    D. Sodi-Pallares, M. R. Testelli, B. L. Fishleder, A. Bisteni, G. A. Medrano, C. Friedland and A. de Micheli, Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report, Am.J.Cardiol. 9:166 (1962).PubMedCrossRefGoogle Scholar
  23. 23.
    W. J. Rogers, P. H. Segall, H. G. McDaniel, J. A. Mantle, R. O. Russell and C. E. Rackley, Prospective randomized trial of glucose-insulin-potassium in acute myocardial infarction. Effects on myocardial hemodynamics, substrates and rhythm, Am.J.Cardiol. 43:801–809 (1979).PubMedCrossRefGoogle Scholar
  24. 24.
    R. Roberts, V. deMello and B. E. Sobel, Deleterious effects of methylprednisolone in patients with myocardial infarction, Circulation 53, Suppl I:204–206 (1976).Google Scholar
  25. 25.
    J. K. Kjekshus and P. Grøttum, Effect of inhibition of lipolysis on infarct size in man, in:”Acute and Long-term Medical Management of Myocardial Ischaemia,” A. Hjalmarson and L. Wilhelmsen, eds., AB Hässle, Mölndal, Sweden, pp.373–387 (1978).Google Scholar
  26. 26.
    J. P. Derrida, R. Sal and P. Chiche, Favorable effects of prolonged nitroglycerin infusion in patients with acute myocardial infarction, Am.Heart J. 96:833–834 (1978).PubMedCrossRefGoogle Scholar
  27. 27.
    W-D. Bussman, D. Passek, W. Seidel and M. Kaltenbach, Reduction of creatine kinase, creatine kinase-MB, and infarct size by intravenous nitroglycerin, Adv.Clin.Cardiol. 1:536–541 (1980).Google Scholar
  28. 28.
    J. D. Durrer, K. I. Lie, F. J. L. van Capelle and D. Durrer, Effect of sodium nitroprusside on mortality in acute myocardial infarction, New Engl.J.Med. 306:1121–1128 (1982).PubMedCrossRefGoogle Scholar
  29. 29.
    J. N. Cohn, J. A. Franciosa, G. S. Francis, D. Archibald, F. Tristani, R. Fletcher, A. Montero, G. Cintron, J. Clarke, D. Hager, R. Saunders, F. Cobb, R. Smith, H. Loeb and H. Settle, Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure. Results of a Veterans Administration Cooperative Study, New Engl.J.Med. 306:1129–1135 (1982).PubMedCrossRefGoogle Scholar
  30. 30.
    P. D. Snow, Effect of propranolol in myocardial infarction, Lancet ii:551–553 (1965).CrossRefGoogle Scholar
  31. 31.
    T. Peter, R. M. Norris, E. D. Clarke, M. K. Heng, B. N. Singh, B. Williams, D. R. Howell and P. K. Ambler, Reduction of enzyme levels by propranolol after acute myocardial infarction, Circulation 57:1091–1095 (1978).PubMedCrossRefGoogle Scholar
  32. 32.
    H. J. Jürgensen, J. Frederiksen, D. A. Hansen and O. Pedersen-Bjergaard, Effekten af alprenolol på myokarde-infarktstørrelsen bedømt ud fra seriebestemmelser af serum-kreatinkinase, Ugeskrf.laeg. 141:3089–3091 (1979).Google Scholar
  33. 33.
    M. P. Andersen, P. Bechsgaard, J. Frederiksen, D. A. Hansen, H. J. Jlirgensen, B. Nielsen, F. Pedersen, O. Pedersen-Bjergaard and S. L. Rasmussen, Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction, Lancet ii:865–872 (1979).CrossRefGoogle Scholar
  34. 34.
    P. Sleight, S. Yusuf, R. Peto, P. Rossi, D. Ramsale, D. Bennett, C. Bray and L. Furse, Early intravenous atenolol treatment in suspected acute myocardial infarction, Acta Med.Scand. Suppl 651:185–191 (1981).Google Scholar
  35. 35.
    P. Mathes, C. Cowan and S. Gudbjarnason, Storage and metabolism of norepinephrine after experimental myocardial infarction, Am.J.Physiol. 220:27 (1971).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • A. Waldenström
    • 1
  • J. Herlitz
    • 1
  • F. Waggstein
    • 1
  • Å. Hjalmarson
    • 1
  1. 1.Department of Medicine I Sahlgren’s HospitalUniversity of GöteborgGöteborgSweden

Personalised recommendations